Similar articles for PMID: 8326384

Year	Number of Results
1986	1
1987	1
1988	4
1989	7
1990	12
1991	24
1992	24
1993	39
1994	38
1995	28
1996	33
1997	25
1998	14
1999	13
2000	13
2001	4
2002	5
2003	4
2004	8
2005	5
2006	4
2007	5
2008	14
2009	7
2010	8
2011	11
2012	9
2013	6
2015	1
2016	3
2017	2
2018	1
2020	1
2021	2
2022	2
2023	0

1

Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease.

Ichise M, Toyama H, Fornazzari L, Ballinger JR, Kirsh JC. Ichise M, et al. J Nucl Med. 1993 Aug;34(8):1274-81. J Nucl Med. 1993. PMID: 8326384 Free article.

2

[Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].

Saur HB, Bartenstein P, Schober O, Oberwittler C, Lerch H, Masur H. Saur HB, et al. Nuklearmedizin. 1994 Oct;33(5):184-8. Nuklearmedizin. 1994. PMID: 7997375 Clinical Trial. German.

3

Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease.

Knable MB, Jones DW, Coppola R, Hyde TM, Lee KS, Gorey J, Weinberger DR. Knable MB, et al. J Nucl Med. 1995 Jul;36(7):1216-25. J Nucl Med. 1995. PMID: 7790947 Free article.

4

Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.

Scherfler C, Scholz SW, Donnemiller E, Decristoforo C, Oberladstätter M, Stefanova N, Diederen E, Virgolini I, Poewe W, Wenning GK. Scherfler C, et al. Neuroimage. 2005 Feb 1;24(3):822-31. doi: 10.1016/j.neuroimage.2004.10.005. Epub 2004 Nov 24. Neuroimage. 2005. PMID: 15652317

5

Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease.

Pirker W, Asenbaum S, Wenger S, Kornhuber J, Angelberger P, Deecke L, Podreka I, Brücke T. Pirker W, et al. J Nucl Med. 1997 Nov;38(11):1711-7. J Nucl Med. 1997. PMID: 9374338 Free article.

6

[Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].

Reiche W, Grundmann M, Huber G. Reiche W, et al. Radiologe. 1995 Nov;35(11):838-43. Radiologe. 1995. PMID: 8657887 German.

7

Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans.

Toyama H, Ichise M, Ballinger JR, Fornazzari L, Kirsh JC. Toyama H, et al. Ann Nucl Med. 1993 Feb;7(1):29-38. doi: 10.1007/BF03164789. Ann Nucl Med. 1993. PMID: 8461237

8

SPECT study of the nigrostriatal dopaminergic system in Huntington's disease.

Hwang WJ, Yao WJ. Hwang WJ, et al. J Neuroimaging. 2013 Apr;23(2):192-6. doi: 10.1111/j.1552-6569.2011.00671.x. Epub 2011 Dec 30. J Neuroimaging. 2013. PMID: 22211920

9

Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.

Leslie WD, Abrams DN, Greenberg CR, Hobson D. Leslie WD, et al. J Nucl Med. 1996 Oct;37(10):1589-91. J Nucl Med. 1996. PMID: 8862288 Free article.

10

Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.

Brücke T, Podreka I, Angelberger P, Wenger S, Topitz A, Küfferle B, Müller C, Deecke L. Brücke T, et al. J Cereb Blood Flow Metab. 1991 Mar;11(2):220-8. doi: 10.1038/jcbfm.1991.53. J Cereb Blood Flow Metab. 1991. PMID: 1671782

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed